Stryker Corporation $SYK Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 2.6% in the third quarter, Holdings Channel reports. The firm owned 160,694 shares of the medical technology company’s stock after acquiring an additional 4,019 shares during the period. Federated Hermes Inc.’s holdings in Stryker were worth $59,404,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Mid American Wealth Advisory Group Inc. purchased a new stake in Stryker during the second quarter worth approximately $26,000. Clayton Financial Group LLC acquired a new stake in Stryker in the 3rd quarter valued at $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker during the second quarter worth about $28,000. Sachetta LLC boosted its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the period. Finally, Kilter Group LLC acquired a new stake in shares of Stryker in the second quarter valued at about $29,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 1.0%

NYSE SYK opened at $354.39 on Friday. The company has a market capitalization of $135.52 billion, a price-to-earnings ratio of 46.57, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The company’s fifty day moving average price is $359.38 and its two-hundred day moving average price is $371.95.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the business posted $4.01 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is a boost from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio (DPR) is 46.25%.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Insider Activity

In related news, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on SYK. Wells Fargo & Company boosted their price target on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Sanford C. Bernstein upped their target price on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Citigroup lowered their price target on shares of Stryker from $455.00 to $420.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $425.94.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.